Boscia J A, Korzeniowski O M, Kobasa W D, Rocha H, Levison M E, Kaye D
J Antimicrob Chemother. 1983 Oct;12(4):407-10. doi: 10.1093/jac/12.4.407.
The pharmacokinetics of cefoperazone were studied and compared in four normal subjects and six patients with hepatosplenic schistosomiasis (HSS) with mild liver disease but marked portal hypertension. All subjects received a 2 g intravenous infusion of cefoperazone over 15 min. Although most pharmacokinetic parameters did not differ significantly between normal subjects and patients with HSS, the serum beta half-life of cefoperazone was longer in patients with HSS compared to normal subjects (3.0 h vs. 1.7 h). This demonstrates only mild impairment of excretion of cefoperazone in patients with HSS.
对4名正常受试者和6名患有肝脾血吸虫病（HSS）且伴有轻度肝病但门静脉高压显著的患者的头孢哌酮药代动力学进行了研究和比较。所有受试者均在15分钟内静脉输注2g头孢哌酮。虽然正常受试者和HSS患者之间的大多数药代动力学参数没有显著差异，但与正常受试者相比，HSS患者的头孢哌酮血清β半衰期更长（3.0小时对1.7小时）。这表明HSS患者中头孢哌酮的排泄仅有轻度受损。
